Proteome Factory AG, Berlin, Germany.
Transition Technologies Science, Warsaw, Poland.
Nat Commun. 2023 Nov 23;14(1):7664. doi: 10.1038/s41467-023-42855-6.
We present a comprehensive multi-omic analysis of the EPISTOP prospective clinical trial of early intervention with vigabatrin for pre-symptomatic epilepsy treatment in Tuberous Sclerosis Complex (TSC), in which 93 infants with TSC were followed from birth to age 2 years, seeking biomarkers of epilepsy development. Vigabatrin had profound effects on many metabolites, increasing serum deoxycytidine monophosphate (dCMP) levels 52-fold. Most serum proteins and metabolites, and blood RNA species showed significant change with age. Thirty-nine proteins, metabolites, and genes showed significant differences between age-matched control and TSC infants. Six also showed a progressive difference in expression between control, TSC without epilepsy, and TSC with epilepsy groups. A multivariate approach using enrollment samples identified multiple 3-variable predictors of epilepsy, with the best having a positive predictive value of 0.987. This rich dataset will enable further discovery and analysis of developmental effects, and associations with seizure development in TSC.
我们对 EPISTOP 前瞻性临床试验进行了全面的多组学分析,该试验研究了氨己烯酸对结节性硬化症(TSC)患者进行症状前癫痫治疗的早期干预作用。93 名 TSC 婴儿从出生到 2 岁接受了随访,以寻找癫痫发展的生物标志物。氨己烯酸对许多代谢物有深远影响,使血清脱氧胞苷单磷酸(dCMP)水平增加了 52 倍。大多数血清蛋白和代谢物以及血液 RNA 种类随年龄变化显著。39 种蛋白质、代谢物和基因在年龄匹配的对照组和 TSC 婴儿之间存在显著差异。其中 6 种在对照组、无癫痫 TSC 组和癫痫 TSC 组之间的表达也存在逐渐差异。使用入组样本的多元方法确定了多个 3 变量癫痫预测因子,其中最佳预测因子的阳性预测值为 0.987。这个丰富的数据集将能够进一步发现和分析发育效应,并与 TSC 中的癫痫发作发展相关联。